Minocycline-induced hyperpigmentation in rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 14, Issue 1, 2008, Pages 17-20

  Fay, Brian T ^a,c   Whiddon, Annemarie P ^a   Puumala, Susan ^b   Black, Natalie A ^a   O'Dell, James R ^a   Mikuls, Ted R ^a  

^a Department of Internal Medicine ^*  (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Hyperpigmentation; Minocycline; Rheumatoid arthritis; Tetracycline

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PREDNISONE; WARFARIN; ANTIRHEUMATIC AGENT;

ADULT; ARM; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEAD; HUMAN; HYPERPIGMENTATION; LEG; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NAUSEA; NECK; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; AGE; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PROPORTIONAL HAZARDS MODEL; PUBLIC HOSPITAL; UNITED STATES;

ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HOSPITALS, UNIVERSITY; HOSPITALS, VETERANS; HUMANS; HYPERPIGMENTATION; MALE; MIDDLE AGED; MINOCYCLINE; NEBRASKA; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 44449084363     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31816356d1     Document Type: Article

References (26)

1. Tilley B, Alarcon G, Heyse S, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial MIRA Trial Group. Ann Intern Med. 1995;122:81-89.
2. O'Dell J, Haire C, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 1997;40:842-848.
3. O'Dell J, Blakely K, Mallek J, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum. 2001;44:2235-2241.
4. Kloppenburg M, Breedveld F, Terwiel J, et al. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum. 1994;5:629-636.
5. Greenwald R, Moak S, Ramamurthy N, et al. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen ameliorate bone damage. J Rheumatol. 1992;19: 927-928.
6. Greenwald R. Treatment of destructive arthritis with MMP inhibitors: potential role of tetracyclines. Ann N Y Acad Sci. 1994;732:181-198.
7. Golub L, Evans R, McNamara T, et al. A non-microbial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphymonas gingivalis induced periodontitis in rats. Ann N Y Acad Sci. 1994; 732:96-111.
8. Ritchlin CT, Haas-Smith SA, Schwarz EM, et al. Minocycline but not doxycycline upregulates IL-10 production in human synoviocytes, mononuclear cells and synovial explants -abstract-. Arthritis Rheum. 2000;43(suppl 9):S345.
9. Golub L, Ramamurthy N, McNamara T, et al. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991;2:297-321.
10. Vernillo A, Ramamurthy N, Golub L, et al. The nonantimicrobial properties of tetracycline for the treatment of periodontal diseases. Curr Opin Periodontol. 1994;2:111-118.
11. Greenwald R. Tetracyclines may be therapeutically beneficial in rheumatoid arthritis, but not for the reasons you might think. J Clin Rheumatol. 1995;1:185-189.
12. Amin A, Attur M, Thakker G, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide syntheses. Proc Natl Acad Sci USA. 1996;93:14014-14019.
13. Martin R, Warr G, Couch R, et al. Effects of tetracycline on leukotaxis. J Infect Dis. 1974;129:110-116.
14. Forsgren A, Schmeling D, Quie P. Effects of tetracycline on the phagocytic function of human leukocytes. J Infect Dis. 1974;130:412-415.
15. Mouton R, Jordaan H, Schneider J. A new type of minocycline-induced cutaneous hyperpigmentation. Clin Exp Dermatol. 2004;29:8-14.
16. Ozog D, Gogstetter D, Scott G, et al. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol. 2000;136:1133-1138.
17. Roberts G, Capell H. The frequency and distribution of minocyclineinduced hyperpigmentation in a rheumatoid arthritis population. J Rheumatol. 2006;33:1254-1257.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
19. Gooley T, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
20. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51:524-532.
21. Langevitz P, Livneh A, Bank I, et al. Benefits and risks of minocycline in rheumatoid arthritis. Drug Safety. 2000;22:405-414.
22. Alster T, Gupta S. Minocycline-induced hyperpigmentation treated with a 755-nm q-switched alexandrite laser. Dermatol Surg. 2004;30:1201-1204.
23. Argenyi Z, Finelli L, Bergfeld W, et al. Minocycline-related cutaneous hyperpigmentation as demonstrated by light microscopy, electron microscopy, and x-ray energy spectroscopy. J Cutan Pathol. 1987;14:176-180.
24. Sato S, Murphy G, Bernhard J, et al. Ultrastructural and x-ray microanalytical observations of minocycline-related hyperpigmentation of the skin. J Invest Dermatol. 1981;77:264-271.
25. Okada N, Sato S, Sasou T, et al. Characterizations of pigmented granules in minocycline-induced cutaneous pigmentation. Observations using fluorescence microscopy and high-performance liquid chromatography. Br J Dermatol. 1993;129:403-407.
26. Bowles W. Protection against minocycline pigment formation by ascorbic acid (vitamin C). J Esthet Dent. 1998;10:182-186.